Skip to main content
. 2019 Sep 27;18(6):5811–5820. doi: 10.3892/ol.2019.10929

Table III.

Hematological toxicity of VTD regimen.

1–2 grade adverse events 3–4 grade adverse events


Hematological toxicity Number, n Percentage (n=205) Number, n Percentage (n=205)
Neutropenia 1 0.5 5 2.5
Thrombocytopenia 4 2.0 1 0.5
Anemia 12 6.0

VTD, bortezomib, thalidomide, dexamethasone.